Fighting to Preserve the Benefits of the 340B Program
On June 21, 2024, the American Journal of Managed Care ran an article titled “Protecting the 340B Program Vital for Providing the Best Care to Patients With HIV” that detailed…
On June 11, 2024, the Times West Virginian ran a story titled “Federal drug pricing program 340B important for rural health care providers in W.Va.” which articulates and underscores the…
On July 24, 2024, two hospital-covered entities sued the Health Resources and Services Administration (“HRSA”), arguing that HRSA’s approval of J&J’s 340B audit request against them was unlawful and premature. The…
Alkermes and Viatris have become the 36th and 37th manufacturers, respectively, to impose restrictions on contract pharmacy arrangements. These restrictions are effective July 22 and August 1, respectively, but please…
RWC-340B Fact Sheet – Oppose 340B ACCESS Act
RWC-340B was asked to sign onto the attached letter to CMS commenting on its May 3, 2024 Draft Guidance implementing aspects of the Inflation Reduction Act (IRA). 340B Health drafted the…
RWC-340B Comparison of 340B Principles and Legislation Chart. Comparison of 340B Principles and Legislation Chart.pdf
RWC-340B releases press statement urging Congress to soundly reject House Republicans “340B Access Act”. “Disguised as a genuine reform effort, the bill would diminish the program’s benefits to favor drug…
Today, the D.C. Circuit Court of Appeals issued its decision regarding HRSA’s enforcement authority to prevent contract pharmacy restrictions imposed by Novartis and United Therapeutics. Novartis limits hospital covered entities…
RWC-340B carefully reviewed the draft legislation, explanatory statement, and supplemental request for information (RFI) that the Bipartisan 340B Senate Working Group (Working Group) shared with 340B stakeholders on February 2,…